Dubai- UAE: The United Arab Emirates is shifting towards re-evaluating its medicine pricing model as there is an increasing worry regarding the cost of medicine, the existence of price differences and accessibility of the medication by patients, officials and lawmakers have affirmed. The matter has been put in the limelight in a recent session of the Federal National Council (FNC) where members expressed the recurring discrepancies between the official price lists and actual prices that patients pay at the private pharmacies.
Regardless of the available regulations and integrated procurement systems, it can be seen that a vast majority of medicines in the UAE are much more expensive than those in the neighbouring countries and the international markets. Such medicine pricing variations have brought concerns over transparency, enforcement and effectiveness of the existing pharmaceutical policies.
A Medicine Pricing Framework Under Analysis
At the center of the argument is the fact that, despite the presence of an official list of prices on medicines, under federal regulations, patients are occasionally charged a high price, especially with the most necessary and of high demand drugs. Lawmakers emphasized that even though unified procurement mechanisms have the theoretical effect of restricting the cost differences, lax monitoring and enforcing leave certain products at price levels that are above their authorized prices, in particular in the private sector.
FNC member Naama Al Sharhan highlighted that the reconsideration of the policies on medicine pricing will directly and positively affect patients, with a particular effect on those who struggle with such chronic diseases as diabetes and high blood pressure. She explained the reaction of the health minister to be open and adaptable, and admitted that the improvement will be conditioned by follow-through and specific changes in the prices of certain drugs.
The opening of policy suggestions into precise guidance and a reassessment of the prices of particular medicines are the indicators of a change, and when it happens, we will understand that we are on the right track, Al Sharhan said, highlighting the connection between the changes in policies and the outcomes of patient treatment.
Openness, Observation And Patient Trust
One of the themes present throughout the session was the necessity of increased level of transparency and control. Even though the rules on medicine pricing are said to be harmonized at a federal level, gaps in the observation have still created differences in pharmacies. Lawmakers indicated that the difference in prices in comparison to other markets should be small -and hopefully nonexistent.
Such a perception was restated by the FNC member Mohammed Al Kashf and he added that the extreme pricing is especially problematic where giant businesses utilise market power to hike prices. He noted that certain medicines particularly during times of high demand like the COVID-19 pandemic experienced overcharging which was not even close to the official listed prices.
The pricing model is present, though with rising demand, there are medicines that are overpriced, which Al Kashf pointed to as the necessity to have more effective regulatory tools.
Local Production: A Part Of The Solution
In addition to short-term price regulation, legislators and authorities also promoted the creation of the pharma industry at the local level. The Emirates Drug Establishment that is entering into pricing regulations in these discussions brought to the limelight activities meant to promote local manufacture of vital medicines especially those used in management of chronic illnesses.
Advocates believe that increasing local production would enhance the security of drugs in the long term, decrease reliance on imports, and finally lead to the reduction of medicine pricing. Al Sharhan mentioned that UAE-produced medicines are of global quality and can help enhance consumer confidence, although the perception regarding the local products remains unequal.
Increasing openness on medicine information, she said, would enable the production of a healthier and competitive market that would be beneficial both to the consumers and producers.
Agreeing On The Path Forward
Authorities stated that there is a multi-tier committee of officials, which has been formed to research on the pricing mechanisms and market regulation. Representatives of the health ministers were reported to have agreed with all the recommendations of the council and gave commitments of following up on the same until implementation.
To most observers, the final test of the success of this review will be whether patients, in particular, those dependent on long-term medication, will actually be able to observe the reduction in unfair medicine pricing in pharmacies in the UAE. As the publicity increases and the political desire is achieved, the reforms are not only focused on affordability, but also on the national security of drugs and transparency of the market.
Also read: India–UAE Comprehensive Strategic Partnership Enters A New Era
